A phase II study of AN2-502998
Latest Information Update: 13 Aug 2025
At a glance
- Drugs AN2 502998 (Primary)
- Indications Chagas disease
- Focus Proof of concept; Therapeutic Use
Most Recent Events
- 13 Aug 2025 New trial record
- 12 Aug 2025 According to AN2 Therapeutics media release, data expected in 2027.
- 23 Jul 2025 Accoridng to a Drugs for Neglected Diseases initiative (DNDi) media release, company expects phase II study initiation planned in 2026.